0001104659-23-070148.txt : 20230612 0001104659-23-070148.hdr.sgml : 20230612 20230612070518 ACCESSION NUMBER: 0001104659-23-070148 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230612 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230612 DATE AS OF CHANGE: 20230612 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MedTech Acquisition Corp CENTRAL INDEX KEY: 0001826667 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 853009869 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39813 FILM NUMBER: 231007076 BUSINESS ADDRESS: STREET 1: 48 MAPLE AVENUE CITY: GREENWICH STATE: CT ZIP: 06830 BUSINESS PHONE: 6462096063 MAIL ADDRESS: STREET 1: 48 MAPLE AVENUE CITY: GREENWICH STATE: CT ZIP: 06830 8-K 1 tm2318362d1_8k.htm FORM 8-K
0001826667 false 0001826667 2023-06-12 2023-06-12 0001826667 MTAC:UnitsEachConsistingOfOneShareOfClassACommonStockAndOneThirdOfOneRedeemableWarrantMember 2023-06-12 2023-06-12 0001826667 us-gaap:CommonClassAMember 2023-06-12 2023-06-12 0001826667 us-gaap:WarrantMember 2023-06-12 2023-06-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 12, 2023

 

MedTech Acquisition Corporation

(Exact name of registrant as specified in its charter)

 

Delaware   001-39813   85-3009869
(State or other jurisdiction of
incorporation)		   (Commission File Number)   (I.R.S. Employer
Identification No.)

 

48 Maple Avenue,
Greenwich, CT		   06830
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (908) 391-1288

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

 

x Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)		   Name of each exchange on
which registered
Units, each consisting of one share of Class A common stock and one-third of one Redeemable Warrant   MTACU   The Nasdaq Stock Market LLC
Class A common stock, par value $0.0001 per share   MTAC   The Nasdaq Stock Market LLC
Warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share   MTACW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ 

 

 

 

 

  

Item 7.01 Regulation FD Disclosure.

 

On November 11, 2022, MedTech Acquisition Corporation, a Delaware corporation (“MTAC”), entered into an Agreement and Plan of Merger, as amended pursuant to that certain First Amendment to Agreement and Plan of Merger, dated April 4, 2023, and that certain Second Amendment to Agreement and Plan of Merger, dated May 13, 2023 (as amended, the “Merger Agreement”), with MTAC Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of MTAC (“Merger Sub”), and TriSalus Life Sciences, Inc., a Delaware corporation (“TriSalus”), pursuant to which, subject to the satisfaction or waiver of certain conditions set forth therein, Merger Sub will merge with and into TriSalus (the “Merger”), with TriSalus surviving the Merger as a wholly owned subsidiary of MTAC, and with TriSalus’ equity holders receiving shares of MTAC common stock, par value $0.0001 per share (the transactions contemplated by the Merger Agreement and the related ancillary agreements, the “Business Combination”). Upon consummation of the Business Combination, MTAC will be renamed “TriSalus Life Sciences, Inc.”

 

On June 12, 2023, MTAC and TriSalus issued a joint press release and made social media posts announcing that TriSalus presented additional data related to its ongoing Pressure-Enabled Regional Immuno-Oncology-01 clinical study for uveal melanoma with liver metastases at the American Society of Clinical Oncology 2023 Annual Meeting. The press release and social media posts are furnished hereto as Exhibit 99.1 and Exhibit 99.2, respectively.

 

The information in this Item 7.01, including Exhibit 99.1 and Exhibit 99.2, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liabilities under that section, and shall not be deemed to be incorporated by reference into the filings of MTAC under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or the Exchange Act, regardless of any general incorporation language in such filings. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information in this Item 7.01, including Exhibit 99.1 and Exhibit 99.2.

 

Changes and Additional Information in Connection with SEC Filing

 

In connection with the Merger Agreement and the proposed Business Combination, MTAC filed with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 (File No. 333-269138) (as amended, the “Registration Statement”), which includes a proxy statement/prospectus of MTAC that will be both the proxy statement to be distributed to holders of MTAC’s common stock in connection with its solicitation of proxies for the vote by MTAC’s stockholders with respect to the Business Combination and other matters as may be described in the Registration Statement, as well as the prospectus relating to the offer and sale of the securities to be issued in the Business Combination. The Registration Statement is not yet effective. The Registration Statement, including the proxy statement/prospectus contained therein, when it is declared effective by the SEC, will contain important information about the Business Combination and the other matters to be voted upon at a meeting of MTAC’s stockholders to be held to approve the Business Combination and other matters (the “Special Meeting”). MTAC may also file other documents with the SEC regarding the Business Combination. MTAC stockholders and other interested persons are advised to read, when available, the Registration Statement, including the proxy statement/prospectus contained therein, as well as any amendments or supplements thereto, because they will contain important information about the Business Combination. When available, the definitive proxy statement/prospectus will be mailed to MTAC stockholders as of a record date to be established for voting on the Business Combination and the other matters to be voted upon at the Special Meeting.

 

 

 

 

Participation in Solicitation

 

MTAC and TriSalus and their respective directors and executive officers, under SEC rules, may be deemed to be participants in the solicitation of proxies of MTAC’s stockholders in connection with the Business Combination. Investors and security holders may obtain more detailed information regarding the names and interests in the Business Combination of MTAC’s directors and officers in MTAC’s filings with the SEC, including MTAC’s registration statement on Form S-1, which was originally filed with the SEC on November 30, 2020, as amended, MTAC’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on March 22, 2023, and the Registration Statement. To the extent that holdings of MTAC’s securities have changed from the amounts reported in the Registration Statement, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies from MTAC’s stockholders in connection with the Business Combination are included in the Registration Statement and will be set forth in the definitive proxy statement/prospectus forming a part of the Registration Statement. Investors and security holders of MTAC and TriSalus are urged to carefully read in their entirety the proxy statement/prospectus and other relevant documents that will be filed with the SEC, when they become available, because they will contain important information about the Business Combination.

  

Investors and security holders will be able to obtain free copies of the proxy statement/prospectus and other documents containing important information about MTAC and TriSalus through the website maintained by the SEC at www.sec.gov. Copies of the documents filed with the SEC by MTAC can be obtained free of charge by directing a written request to MedTech Acquisition Corporation at 48 Maple Avenue, Greenwich, CT 06830.

 

INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED OR DISAPPROVED BY THE SEC OR ANY OTHER REGULATORY AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING THEREOF OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

 

Forward-Looking Statements

 

This Current Report on Form 8-K contains certain “forward-looking statements” within the meaning of the United States federal securities laws regarding MTAC’s or TriSalus’ expectations, hopes, beliefs, assumptions, intentions or strategies regarding the future including, without limitation, statements regarding: (i) the tolerability of SD-101 infusion with TriSalus’ TriNav Infusion System (“TriNav”), (ii) the potential of TriSalus’ proprietary Pressure-Enabled Drug Delivery™ method to enable SD-101 to have broad immune effects, including depletion of myeloid-delivered suppressor cells, within the liver and systemically, (iii) immunological changes within the liver as evidence of disease control and (iv) expectations for continuing program development. These forward-looking statements generally are identified by words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would,” “will” and similar expressions or the negative or other variations of such statements. These statements are predictions, projections and other statements about future events that are based on various assumptions, whether or not identified in this Current Report on Form 8-K and on the current expectations of MTAC’s and TriSalus’ respective managements and are not predictions of actual performance and, as a result, are subject to risks and uncertainties.

 

 

 

 

Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: (i) the risk that the Business Combination may not be completed in a timely manner or at all, which may adversely affect the price of MTAC’s securities; (ii) the risk that the Business Combination may not be completed by MTAC’s business combination deadline and the potential failure to obtain an extension of the business combination deadline; (iii) the failure to satisfy the conditions to the consummation of the Business Combination, including the approval of the Merger Agreement by the stockholders of MTAC, the satisfaction of the minimum cash amount following any redemptions by MTAC’s public stockholders, and the receipt of certain governmental and regulatory approvals; (iv) the lack of a third-party valuation in determining whether or not to pursue the Business Combination on the terms set forth in the Merger Agreement; (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; (vi) the receipt of an unsolicited offer from another party for an alternative transaction that could interfere with the Business Combination; (vii) the effect of the announcement or pendency of the Business Combination on TriSalus’ business relationships, operating results and business generally; (viii) the risk that the Business Combination disrupts current plans and operations of TriSalus; (ix) the outcome of any legal proceedings that may be instituted against TriSalus or MTAC related to the Merger Agreement or the Business Combination; (x) the ability to maintain the listing of MTAC’s securities on the Nasdaq; (xi) changes in business, market, financial, political and legal conditions; (xii) unfavorable changes in the reimbursement environment for TriSalus’ products; (xiii) TriSalus’ product candidates not achieving success in preclinical or clinical trials or not being able to obtain regulatory approval, either on a timely basis or at all or subject to any conditions that negatively impact TriSalus’ ability to commercialize the applicable product candidates; (xiv) TriSalus being unable to continue to grow TriNav sales; (xv) the size of the addressable markets for TriNav and SD-101, if successfully developed and approved by the applicable regulatory authorities, being less than TriSalus currently estimates; (xvi) TriSalus’ ability to successfully commercialize any product candidates that it successfully develops and that are approved by applicable regulatory authorities; (xvii) TriSalus’ ability to continue to fund preclinical and clinical trials for SD-101; (xviii) TriSalus’ ability to partner with other companies; (xix) future economic and market conditions; (xx) the development, effects and enforcement of laws and regulations affecting TriSalus’ business or industry; (xxi) TriSalus’ ability to manage future growth; (xxii) TriSalus’ ability to maintain and grow its market share; (xxiii) the effects of competition on TriSalus’ business; (xxiv) the ability of MTAC or the combined company to raise additional financing in connection with the Business Combination or to finance its operations in the future; (xxv) the ability to implement business plans, forecasts and other expectations after the completion of the Business Combination, and identify and realize additional opportunities; (xxvi) costs related to the Business Combination; (xxvii) the failure to realize the anticipated benefits of the Business Combination or to realize estimated pro forma results and the underlying assumptions, including with respect to estimated stockholder redemptions; and (xxviii) other risks and uncertainties indicated from time to time in the Registration Statement, including those under the “Risk Factors” section therein and in MTAC’s other filings with the SEC. The foregoing list of factors is not exclusive.

  

MTAC’s other SEC filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and none of MTAC, TriSalus, or any of their respective representatives assume any obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. None of MTAC, TriSalus, or any of their respective representatives gives any assurance that either MTAC or TriSalus will achieve its expectations.

 

No Offer or Solicitation

 

This Current Report on Form 8-K shall not constitute an offer to sell, a solicitation of an offer to buy or a recommendation to purchase any securities, or the solicitation of any proxy, vote, consent or approval in any jurisdiction in connection with the Business Combination, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdictions. This communication is restricted by law; it is not intended for distribution to, or use by any person in, any jurisdiction where such distribution or use would be contrary to local law or regulation. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

 

 

 

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
No.		   Description
99.1   Press Release, dated June 12, 2023.
99.2   Social Media Posts.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MedTech Acquisition Corporation
   
Dated: June 12, 2023 By: /s/ Christopher C. Dewey
    Name: Christopher C. Dewey
    Title: Chief Executive Officer

 

 

 

 EX-99.1 2 tm2318362d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

FOR IMMEDIATE RELEASE

 

TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD™ Method with the TriNav™ Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting

 

New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment and decreased circulating tumor DNA (ctDNA) levels

 

DENVER and CHICAGO, June 12, 2023 – TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company in the process of going public through a business combination transaction (the Business Combination) with MedTech Acquisition Corporation (Nasdaq: MTAC) (MedTech or MTAC), today announced additional Phase 1 clinical data presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting taking place in Chicago, Illinois, from June 2-6, 2023.

 

TriSalus’ ongoing Phase 1 Pressure-Enabled Regional Immuno-Oncology (PERIO-01) (NCT04935229) clinical study for uveal melanoma with liver metastases (UMLM) is studying an investigational class C toll-like receptor-9 agonist, SD-101, delivered intravascularly by TriSalus’ TriNav® Infusion System (TriNav) using the Company’s proprietary Pressure-Enabled Drug Delivery™ (PEDD) method of administration. PERIO-01 is evaluating whether this platform approach can improve the performance of systemic checkpoint inhibitors in patients with UMLM.

 

“The data presented by Dr. Kamaneh Montazeri from Mass General Brigham at ASCO reflect important clinical progress of our Phase 1 PERIO-01 trial and builds on the promising data released in April,” said Steven C. Katz, MD, FACS, Chief Medical Officer at TriSalus. “We are pleased that SD-101 in combination with systemic checkpoint inhibition and delivered with TriNav was well tolerated based on a low treatment related serious adverse event rate of 5% and resulted in immune cell activation and natural killer cell expansion. We look forward to moving into Phase 2 later this year and are optimistic about the potential of SD-101 playing an important role in the management of patients with UMLM.”

 

Pharmacokinetic data indicate that the strategy of delivering a toll-like receptor-9 agonist with the PEDD method results in high drug levels in the liver, while the drug is undetectable after four hours in the serum in 97% of patients with available data. The immune effects in liver metastases and the blood are consistent with broad tumor microenvironment modulation and the ability of SD-101 to deplete myeloid derived suppressor cells (MDSCs) in the liver.

 

PERIO-01 is an open-label, first-in-human Phase 1 trial of SD-101, administered by hepatic arterial infusion with TriNav using PEDD in UMLM. The study consists of dose-escalation cohorts of SD-101 (2, 4, or 8 mg) alone or with immune checkpoint inhibition. At the data cutoff as of May 12, 2023, 39 patients were enrolled in the PERIO-01 trial, with each having received at least one dose of SD-101. Of the patients with available data, five patients were treatment-naïve and 81% had failed at least one prior line of therapy, including three patients on their sixth-line of treatment.

 

Following receipt of SD-101, patients demonstrated a statistically significant expansion of peripheral natural killer cells, along with evidence of decreased expression of exhaustion markers on these cells. Increases in serum cytokines, including IFNg and IL-18, also supported systemic immune activation. Additionally, decreased levels of ctDNA levels were observed within eight out of 13 evaluable patients. Stable disease was noted as the best on-treatment response for target lesions in 15 out of 25 patients, with one partial response.

 

 

 

 

These findings, along with reductions of intratumoral MDSCs and decreases in ARG-1 (arginase 1) and IDO-1 (indoleamine 2,3-dioxygenase-1) gene levels, support the hypothesis that SD-101 delivered via PEDD may have favorable immune effects within the liver and systemically.

 

Overall, the data emerging from the PERIO-01 trial continues to indicate immunologic changes are occurring within the liver, with decreases in ctDNA and disease control observed across a group of heavily pre-treated patients with UMLM, as well as a low treatment-related serious adverse event rate.

 

The data were also selected for presentation at the Developmental Therapeutics - Immunotherapy Poster Discussion Session on June 3, 2023 at 3:00pm CT.

 

About TriSalus and Its Proposed Business Combination with MedTech

 

TriSalus is an oncology company integrating immunotherapy with disruptive delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors.

 

TriSalus’ proprietary platform approach addresses immune dysfunction in liver and pancreatic tumors by combining its drug delivery technology with immunotherapeutics. The TriSalus platform comprises the TriNav® Infusion System and SD-101, a class C toll-like receptor 9 (TLR9) agonist. TriNav is an FDA-cleared device that is designed to administer established and emerging therapeutics. SD-101, the Company’s investigational TLR9 agonist, is being delivered via TriNav to selected sites, including tumors in the liver. TriNav is the latest TriSalus asset for the proprietary PEDD method of administration which has been shown to overcome intratumoral pressure through modulation of pressure and flow to increase delivery of therapeutic agents.

 

As previously announced on November 14, 2022, TriSalus entered into a definitive merger agreement (as amended on April 4, 2023 and May 13, 2023) with MedTech, a publicly traded special purpose acquisition company (as amended, the “Merger Agreement”) in connection with the Business Combination. Upon the closing of the transaction, the combined company will be a publicly traded company and its common stock is expected to be listed on the NASDAQ Stock Exchange under the ticker “TLSI.” The transaction is subject to the satisfaction of the necessary regulatory approvals and customary closing conditions, including the approval of MedTech’s shareholders.

 

For Patients

 

To learn more about the clinical trial treatment protocol and enrollment, visit http://www.periotrial.com or http://www.clinicaltrials.gov and search NCT04935229, NCT05220722, and NCT05607953.

 

About MedTech Acquisition Corporation

 

MedTech is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. MedTech has stated a focus on the medical technology industry in the United States and other developed countries.

 

 

 

 

Changes and Additional Information in Connection with SEC Filing

 

The information in this communication has not been reviewed by the U.S. Securities and Exchange Commission (the “SEC”) and certain information may not comply in certain respects with SEC rules. MTAC filed with the SEC a registration statement on Form S-4 (File No. 333-269138) (as amended, the “Registration Statement”), which includes a proxy statement/prospectus of MTAC that will be both the proxy statement to be distributed to holders of MTAC’s common stock in connection with its solicitation of proxies for the vote by MTAC’s stockholders with respect to the Business Combination and other matters as may be described in the Registration Statement, as well as the prospectus relating to the offer and sale of the securities to be issued in the Business Combination. The Registration Statement is not yet effective. The Registration Statement, including the proxy statement/prospectus contained therein, when it is declared effective by the SEC, will contain important information about the Business Combination and the other matters to be voted upon at a meeting of MTAC’s stockholders to be held to approve the Business Combination and other matters (the “Special Meeting”). MTAC may also file other documents with the SEC regarding the Business Combination. MTAC stockholders and other interested persons are advised to read, when available, the Registration Statement, including the proxy statement/prospectus contained therein, as well as any amendments or supplements thereto, because they will contain important information about the Business Combination. When available, the definitive proxy statement/prospectus will be mailed to MTAC stockholders as of a record date to be established for voting on the Business Combination and the other matters to be voted upon at the Special Meeting.

 

Forward-Looking Statements

 

This communication contains certain “forward-looking statements” within the meaning of the United States federal securities laws regarding MTAC’s or TriSalus’ expectations, hopes, beliefs, assumptions, intentions or strategies regarding the future including, without limitation, statements regarding: (i) the tolerability of SD-101 infusion with TriNav, (ii) the potential of TriSalus’ proprietary PEDD method to enable SD-101 to have broad immune effects, including depletion of MDSCs, within the liver and systemically, (iii) immunological changes within the liver as evidence of disease control and (iv) expectations for continuing program development. These forward-looking statements generally are identified by words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would,” “will” and similar expressions or the negative or other variations of such statements. These statements are predictions, projections and other statements about future events that are based on various assumptions, whether or not identified in this communication and on the current expectations of MTAC’s and TriSalus’ respective managements and are not predictions of actual performance and, as a result, are subject to risks and uncertainties.

 

Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: (i) the risk that the Business Combination may not be completed in a timely manner or at all, which may adversely affect the price of MTAC’s securities; (ii) the risk that the Business Combination may not be completed by MTAC’s business combination deadline and the potential failure to obtain an extension of the business combination deadline; (iii) the failure to satisfy the conditions to the consummation of the Business Combination, including the approval of the Merger Agreement, by the stockholders of MTAC, the satisfaction of the minimum cash amount following any redemptions by MTAC’s public stockholders, and the receipt of certain governmental and regulatory approvals; (iv) the lack of a third-party valuation in determining whether or not to pursue the Business Combination on the terms set forth in the Merger Agreement; (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; (vi) the receipt of an unsolicited offer from another party for an alternative transaction that could interfere with the Business Combination; (vii) the effect of the announcement or pendency of the Business Combination on TriSalus’ business relationships, operating results and business generally; (viii) the risk that the Business Combination disrupts current plans and operations of TriSalus; (ix) the outcome of any legal proceedings that may be instituted against TriSalus or MTAC related to the Merger Agreement, or the Business Combination; (x) the ability to maintain the listing of MTAC’s securities on the Nasdaq; (xi) changes in business, market, financial, political and legal conditions; (xii) unfavorable changes in the reimbursement environment for TriSalus’ products; (xiii) TriSalus’ product candidates not achieving success in preclinical or clinical trials or not being able to obtain regulatory approval, either on a timely basis or at all or subject to any conditions that negatively impact TriSalus’ ability to commercialize the applicable product candidates; (xiv) TriSalus being unable to continue to grow TriNav sales; (xv) the size of the addressable markets for TriNav and SD-101, if successfully developed and approved by the applicable regulatory authorities, being less than TriSalus currently estimates; (xvi) TriSalus’ ability to successfully commercialize any product candidates that it successfully develops and that are approved by applicable regulatory authorities; (xvii) TriSalus’ ability to continue to fund preclinical and clinical trials for SD-101; (xviii) TriSalus’ ability to partner with other companies; (xix) future economic and market conditions; (xx) the development, effects and enforcement of laws and regulations affecting TriSalus’ business or industry; (xxi) TriSalus’ ability to manage future growth; (xxii) TriSalus’ ability to maintain and grow its market share; (xxiii) the effects of competition on TriSalus’ business; (xxiv) the ability of MTAC or the combined company to raise additional financing in connection with the Business Combination or to finance its operations in the future; (xxv) the ability to implement business plans, forecasts and other expectations after the completion of the Business Combination, and identify and realize additional opportunities; (xxvi) costs related to the Business Combination; (xxvii) the failure to realize the anticipated benefits of the Business Combination or to realize estimated pro forma results and the underlying assumptions, including with respect to estimated stockholder redemptions; and (xxviii) other risks and uncertainties indicated from time to time in the Registration Statement, including those under the “Risk Factors” section therein and in MTAC’s other filings with the SEC. The foregoing list of factors is not exclusive.

 

 

 

 

MTAC’s other SEC filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and none of MTAC, TriSalus, or any of their respective representatives assume any obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. None of MTAC, TriSalus, or any of their respective representatives gives any assurance that either MTAC or TriSalus will achieve its expectations.

 

Participation in Solicitation

 

MTAC and TriSalus and their respective directors and executive officers, under SEC rules, may be deemed to be participants in the solicitation of proxies of MTAC’s stockholders in connection with the Business Combination. Investors and security holders may obtain more detailed information regarding the names and interests in the Business Combination of MTAC’s directors and officers in MTAC’s filings with the SEC, including MTAC’s registration statement on Form S-1, which was originally filed with the SEC on November 30, 2020, as amended, MTAC’s 2022 Form 10-K, and the Registration Statement. To the extent that holdings of MTAC’s securities have changed from the amounts reported in the Registration Statement, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies from MTAC’s stockholders in connection with the Business Combination are included in the Registration Statement and will be set forth in the definitive proxy statement/prospectus forming a part of the Registration Statement. Investors and security holders of MTAC and TriSalus are urged to carefully read in their entirety the proxy statement/prospectus and other relevant documents that will be filed with the SEC, when they become available, because they will contain important information about the Business Combination.

 

Investors and security holders will be able to obtain free copies of the proxy statement/prospectus and other documents containing important information about MTAC and TriSalus through the website maintained by the SEC at www.sec.gov. Copies of the documents filed with the SEC by MTAC can be obtained free of charge by directing a written request to MedTech Acquisition Corporation at 48 Maple Avenue, Greenwich, CT 06830.

 

INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED OR DISAPPROVED BY THE SEC OR ANY OTHER REGULATORY AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING THEREOF OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

 

 

 

 

Use of Data

 

The data contained herein is derived from various internal and external sources. Neither MTAC nor TriSalus has independently verified the accuracy or completeness of the information derived from external sources. Any market data in the communication involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Further, no representation is made as to the reasonableness of the assumptions made within or the accuracy or completeness of any projections or modeling or any other information contained herein. Any data on past performance or modeling contained herein is preliminary, subject to change and may not be indicative of actual future performance. MTAC and TriSalus assume no obligation to update the information in this communication.

 

No Offer or Solicitation

 

This communication shall not constitute an offer to sell, a solicitation of an offer to buy or a recommendation to purchase any securities, or the solicitation of any proxy, vote, consent or approval in any jurisdiction in connection with the Business Combination, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdictions. This communication is restricted by law; it is not intended for distribution to, or use by any person in, any jurisdiction where such distribution or use would be contrary to local law or regulation. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

 

Media Contact:
press@trisaluslifesci.com

 

Investor Contact:
Aaron Palash / Allison Sobel

 

 

 EX-99.1 3 tm2318362d1_ex99-2.htm EXHIBIT 99.2

Exhibit 99.2

TriSalus Corporate Twitter Post

 

We introduced new clinical data at the #ASCO23 Annual Meeting, supporting our hypothesis that SD-101 delivered via TriNav™ using PEDD™ may have favorable immune effects both within the liver and systemically. Learn more: https://trisaluslifesci.com//recent-news/trisalus-life-sciences-presents-additional-data-for-sd-101-delivered-by-the-proprietary-pedd-method-with-the-trinav-device-for-uveal-melanoma-liver-metastases-at-the-asco-2023-annual/

 

TriSalus Corporate LinkedIn Post

 

We presented new clinical data for our ongoing Phase 1 Pressure-Enabled Regional Immuno-Oncology (PERIO-01) clinical study for uveal melanoma with liver metastases (https://periotrial.com) at the #ASCO23 Annual Meeting. Dr. Kamaneh Montazeri from @Mass General Brigham shared how SD-101 delivered with #TriNav using our proprietary Pressure-Enabled Drug Delivery™ method, in combination with systemic checkpoint inhibition, has demonstrated the ability of SD-101 to deplete liver myeloid derived suppressor cells with disease control and decreased levels of circulating tumor DNA in heavily pre-treated patients. We look forward to moving into Phase 2 of the study later this year. Learn more here: https://trisaluslifesci.com//recent-news/trisalus-life-sciences-presents-additional-data-for-sd-101-delivered-by-the-proprietary-pedd-method-with-the-trinav-device-for-uveal-melanoma-liver-metastases-at-the-asco-2023-annual/

 

 

 EX-101.SCH 4 mtac-20230612.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 mtac-20230612_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 mtac-20230612_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Units, each consisting of one share of Class A common stock and one-third of one Redeemable Warrant [Member] Common Class A [Member] Warrant [Member] Statement [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Units, each consisting of one share of Class A Common Stock and one-third of one Redeemable Warrant EX-101.PRE 7 mtac-20230612_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
Jun. 12, 2023
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 12, 2023
Entity File Number 001-39813
Entity Registrant Name MedTech Acquisition Corporation
Entity Central Index Key 0001826667
Entity Tax Identification Number 85-3009869
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 48 Maple Avenue
Entity Address, City or Town Greenwich
Entity Address, State or Province CT
Entity Address, Postal Zip Code 06830
City Area Code 908
Local Phone Number 391-1288
Written Communications true
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Units, each consisting of one share of Class A common stock and one-third of one Redeemable Warrant [Member]  
Document Information [Line Items]  
Title of 12(b) Security Units, each consisting of one share of Class A common stock and one-third of one Redeemable Warrant
Trading Symbol MTACU
Security Exchange Name NASDAQ
Common Class A [Member]  
Document Information [Line Items]  
Title of 12(b) Security Class A common stock, par value $0.0001 per share
Trading Symbol MTAC
Security Exchange Name NASDAQ
Warrant [Member]  
Document Information [Line Items]  
Title of 12(b) Security Warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share
Trading Symbol MTACW
Security Exchange Name NASDAQ
XML 9 tm2318362d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001826667 2023-06-12 2023-06-12 0001826667 MTAC:UnitsEachConsistingOfOneShareOfClassACommonStockAndOneThirdOfOneRedeemableWarrantMember 2023-06-12 2023-06-12 0001826667 us-gaap:CommonClassAMember 2023-06-12 2023-06-12 0001826667 us-gaap:WarrantMember 2023-06-12 2023-06-12 iso4217:USD shares iso4217:USD shares 0001826667 false 8-K 2023-06-12 MedTech Acquisition Corporation DE 001-39813 85-3009869 48 Maple Avenue Greenwich CT 06830 908 391-1288 true false false false Units, each consisting of one share of Class A common stock and one-third of one Redeemable Warrant MTACU NASDAQ Class A common stock, par value $0.0001 per share MTAC NASDAQ Warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share MTACW NASDAQ true false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 4 23 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://medtechacquisitioncorp.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2318362d1_8k.htm mtac-20230612.xsd mtac-20230612_def.xml mtac-20230612_lab.xml mtac-20230612_pre.xml tm2318362d1_ex99-1.htm tm2318362d1_ex99-2.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2318362d1_8k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 29 }, "contextCount": 4, "dts": { "definitionLink": { "local": [ "mtac-20230612_def.xml" ] }, "inline": { "local": [ "tm2318362d1_8k.htm" ] }, "labelLink": { "local": [ "mtac-20230612_lab.xml" ] }, "presentationLink": { "local": [ "mtac-20230612_pre.xml" ] }, "schema": { "local": [ "mtac-20230612.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 66, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 1, "memberStandard": 2, "nsprefix": "MTAC", "nsuri": "http://medtechacquisitioncorp.com/20230612", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2318362d1_8k.htm", "contextRef": "From2023-06-12to2023-06-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://medtechacquisitioncorp.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2318362d1_8k.htm", "contextRef": "From2023-06-12to2023-06-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "MTAC_UnitsEachConsistingOfOneShareOfClassACommonStockAndOneThirdOfOneRedeemableWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Units, each consisting of one share of Class A Common Stock and one-third of one Redeemable Warrant", "label": "Units, each consisting of one share of Class A common stock and one-third of one Redeemable Warrant [Member]" } } }, "localname": "UnitsEachConsistingOfOneShareOfClassACommonStockAndOneThirdOfOneRedeemableWarrantMember", "nsuri": "http://medtechacquisitioncorp.com/20230612", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medtechacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001104659-23-070148-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-070148-xbrl.zip M4$L#!!0 ( *@XS%:N5LKI^@, )4. 1 ;71A8RTR,#(S,#8Q,BYX MK)DD](EFYZ0-&E?>H0\@#:V9"0Y M0']]1[(-! @!VOA)'_=>S4@STKCQ?I+$Y &4YE(TO;!2]0@()B,N!DWOINN? M=%OMMD?>'__Q.\&O\:?ODS,.<50GIY+Y;=&7[\A_-($Z.0JD\-*^+9'?'\+W<\@(JENKMHSW:$QJ:X'P7@\K@CY M0,=2W>L*D\EV@EU#3:9G:M5)M?BVHU]PS6;D5_3D\R^O[UZM7ME_N)2?Z>]KZ(?S]-V?]T%%Y\G-[1#Q]'Y]7NZW:^9$.S M(224X&$(W?2L?X5[XX.*5(.@5JV&P=U%I^MP7@ZL3V(N[M?!PZ.CH\#-EM 5 MY*2GXE+Z(+#3/:IAIHRS? .>"VVH8(_PD9D1%L&'03[Y",K70M_D4%Y"(UC" M:6"5@7P(< +QM7#TNH1FVA]0FL[@?:I[3K:8<'"_&OH'84G1RJS"<7 ]U#?3 M%/1:0CZUAA89M41[M),X'=AIRZQ:9FW&O+@^:YQ!YQ% U &,#6*>4P4[:94Y0 M(22F#F**$3N6IAQS P=^:]@@JBL9PS4Z16P#DW:;E2PT:$F\ACS"HZ:7-ZTF MKN!4(^ASX4C'1:Z&Q+>9F5FGL>DHC6 9O""1:8@NQ;%KIPHT\IPO'1PHB 7D M"1*C,?&TC\M M+$/L.MHCP:]P.::]75U&"L0OZ&O'ZO]2)S&2=G7RGLT46W2UNAV!^ M/13]Y2ND@8Y+98A8N9DV/3KY<]F1S$EMH-B>7_)\.^2'-;RA*Q,=S2W=Q8CY M-NQF1,G;PX@GG[YU%NBG";;IY\UME][XC&Y8KJ_W"A$F,V'4U'FX99 L4LJ.VXZ=3V:Y@-KN4$I6?B"V MIOJ)X%A?DNUKR#.A4=1=KFZQ5=NW&[P-]3^4#5M2:*X-_DE=]B\%=(=4P66_ M%5.M3_"/*)&B:R2[/Q%8#,#UD*O(X:X@ C2T%\,M58H*=K31E&&9:-1&5YO@L>QA95]]TM0Q]> R^C:/5I1IMQ>8G69]\MRMQ[)A'+1 M-I!8).Y]AN+<9!9]KF2&=7HNQQ&2;V8CR \(FS\ 4$L#!!0 ( *@XS%;1 M;7,\. D %M 5 ;71A8RTR,#(S,#8Q,E]D968N>&ULU9UM4^.V%L?? M=^9^!S=]'4+"TG;ITDXV"YU,=Q=*V-U[[QM&L95$@R)128;DVU?R0_"#CNU0 M$-6^8(-S9/W/^]+[/^>#:9 M3GN!5(A%B'*&3WN,]W[[]3_?!?K?N^_[_>"<8!J=!!]XV)^R!?\E^(S6^"3X M'3,LD.+BE^ KHK$YPL\)Q2*8\/4=Q0KK+]**3X+C@^'/\Z#?[W#>KYA%7'RY MFN[.NU+J3IX,!@\/#P>,WZ,'+F[E0VP\UA]B\M_HX2=GMB M?LR1Q(&.%Y,G&TE.>Z;>K-J'HP,NEH/1X>%P\-]/'V?A"J]1GS 3MQ#W\E+F M++9RP[=OWPZ2;W/3FN5F+FA>Q]$@E[,[L_XV4KL"1>/C0?IET90TG+H@6I(3 MF7CRD8=()2VD55$ 6IC?^KE9WQSJ#T?]H^'!1D:]G%,2;,$IOL*+P/RO0>]J M7>-(X7"%PK]B(HD1%')Q9T@/C.E@PG5+UKJ3DZP$7ISVU@J%NJ[1T>&/PY&I MZ8>2D=K>Z18MB6F0O6!04H%$F NQ&1=K 7S.0V^XWY$UIB9 MQM\+LHJ*GN[.0I@::--!9C.PGN#E=>\JZT=\CHNNE'2A.:NJO\7IN<.\E MMUSTY;4B2O=3F!1X>5V,J_&^TO(R3MLD7J"8JB8JU,Z8^I928JET5Y6-)"3=_,13V( M,O=>XO!@R>\'$28ZDJ/A7V_,QW[Z,0TE)C=YO69H%&N4^8VG"J]E?G**YI@F M5=[H(LTE!O]8]P+)>8(NEOTE0G>)^ &F2N9'$A_ZA\-L%/DA.WQCAG1LI%VC M^6/[*JC/#*MV5V$'S= M,:Q9"'FC'\4X:SF]@(L("SV_.WQ41+G$T6E/B=CB^*O FE DY<5BIGAX.]X0 M6ZNK^ELO\JP(K:-M%5DS P 4Y*N%V>O2*0K]D(W>$!:;[;/RJ$\DVF" <>:M MRB$@HT.?B=P,+?*?"TH^D.[;ZST;M<0["-S14\'5DXA/U^/)S1<=,GF&PM6$ M:_^ETCGSQ>*"X=D*"7RQ2-2-=;*[YBSUA$7ZV^L5$5%B=X4CK),KW5M\0T(@ MICYE,\X:35/="]7V NVA/'T&6#=<<=R-TV"'^]H];N).ZAK8(O(HUFQO;-W3 MOX)GLV2PMWUE&FV79F97;EZVGN;?Q*"N%NPSGR7\^V4@U_JLS1F'L;@Y=ASD M/:?F-KE0E)]E1M$MR&,M*#*BSBE:VJ-<,O$@S'6]+SJ7WC/.'[ ,!;E3A=P! M"'?!TJ>H5V6#/;G[GN0*+_6D022^[":7S5V+M8@'.-KU@UV\>RYCQF)$K_ = M%RTXBI8>4:C)AH+_QGWP_XR14%C0;9?X5XP]0F!3#E$X?H5)CIZ I7>'NV"H M6GO$P2H= O&C>Q"S%:;4/))&K-,54;?W" 8@'L+QT^OB.+LWTPL]AG4GLBOB M*92R?HC+S^ZY7&)!>*1G%*(#D8JQ1RQLRB$*;U^+PAF+NC+(3+TC4-3=]#3+ M-8!S(D-$4XWG^EC+H]&:N4<@[-I?]J[I4V#\#R/1&<7.V#L09>4@!H=9]B06 MHB2OL5^"K#T T2@=).$PKSYCBJBM65WY.0;N4VNSJI4'D;=*!B/N,)E.A>4W M6Y@R2TF;HEZV]";R%ME@]!TFT:FXB?9&(#IE$=[\@;=-X:^8>A-_FVX0@,/D M.55W*<@:B>V,A.W=3M76&P16X2 #AQES*N\:;::1]HDL2+I&NQT%4,0;(DWZ M03 .4^94Y319]LD+=^(G/-97\W;"H\:AHK&@-Y#:O0!1.@[3\4S<9=<*D3_3^[:YK@V>]](U,6#/!QF MYEG[,#=NH 5G)1,/HE[7"P;:8?IMQJ>QP ANZD4+'\)M/(BV53(8<9U!S$N:X6"^^1M04\([C=!E-9D]D#$ M++M[!3RWM)IZ$'18-PC 85H[XY2$Q.PC^J1GLX(@:H]^WC^;5Y20303U6L/"!@E0Q&W&$J^YE?"V3>?#7;KN>Q!U2#8;>8=9:4F8/>LG$@W#7]8*!=IBUYA??V29<(;;$\+H5FZ4'80=E M@]%WF,T^=GW+3GWZTK\^?=FA3W>8S>;"TLT.YO4!@C) M&Y<[D).]<06'SO4'.PRKJ0<88-T@ )=;D^.(*!RE(L\)0RS4J>)NLRAP/Z*M ME ]8NK@ $G+^O/<;IO0/QA_8#"/)&8[29*7IN0I0Q ,V[?I!,,Z? '_E-&8* MB61AL@"N%ZNI-R!LND$ SA_V9@OR=Z-<^@K?)@[V$M[@:) /4G'^$'C*%!8H M5.0>?T *99J;J-A+>$.E03Y(Q?DB[>0"GN@A;LF;UT64#+UA4%<-AM[YVNS9 M&E'Z/I;:"=G8.Y4,O0E]7348>N>KK\_66"QU1_F[X ]JE6VN;D)@+> -"E@] MB,3Y*NNSS>.K(-)=I8T\:M;^P+!+ATC8W'HI$KOWTX2A6523SB18A 3 K;W M@$:+>)"'PU3\0JVP*,[J$GG&H:;E+FVE/R060D/-4O/B*CL:!O&#G 05 M-!AWYYGV93RG)#RG'#7F$04S;Z)>U0P&W7EV_1ZQ6Q'?J7![*7B(L7F,)7?7 M:H>TKM,)O '5W1L0H?NMT8^O1$Y>E2PO8I7\#2>MN/$V24,Y;X"U.@%R>H77 MC\G'C9(X>K^]P@LLS.*4:[Q1[W5EM\T3L];B'E#;SQ<07B&]?S>HN*FKO]7? M9_# J)8 !4 !M=&%C M+3(P,C,P-C$R7VQA8BYX;6S-G5USX[85AN\[T_^ *C?MC&59=IOI.KO):+5V MQA/;T!7[ 5WC+3E%/Q-*.$X9_P']BN.=W,+. MHYAP-&7;AYBD1.S(*CY%_S@<_W.)AL,>Y?Y*:,CXW>U%6>XF31^2T]'HZ>GI MD+)'_,3X?7(8L&V_ NO1NIO86T MH7Q>\KBHXV14V"E+%GNC%GW%21*=)LK>)0MPJKJ]LQH$*N1?PT(VE)N&X^/A MR?CP.0D'Q<%71Y"SF-R2%5+-/$U?'@1*221)&.3;-IRLS&9BSD7&2_&I9I$\IV("(V%A4A;1,@*K&M3$D)==ELZ"6KFQ',T9;[9=SHRJ MS!5.EJK@73)<8_P@*C@>CTB<)L66H=PR/!KGX_=W^>:O, B:FLX=T&&>'/@M?<;;M M92,_D%?U=+4U?8]J[G ;BPBY;"-T>#T2A-SG"PF3*: M1$DJEH^SU8R2^09S,ELI*Q.Q[MLRFMFFH=B[V$0\5+I;$A*Q)%G&Y#/F'-/T MBFR7A&M'XMM690--&P=+4OTMZW%^0EAHG'XNJ=H.$!'UH:"L4)YNG*1JF,JZBY!]]2BO'WW)'/SN4_0/&O2S8Y<=1^/9 MV":T.U/EG.-.:XT1/<.JH,PS8-I&;D!C$Q-PK#0*O(&CS^CDZ0A2 M+E@61R&)%!&_ M_5U^'&8?%0;BSZ^?6+"3%N3]-KY5MYO$%1&Y$,;TBX=NN0TT^IJ6D'1IG>/2 MTZ .3A&"*C'HBXQ"*LPE2 M1:DLKL]VV0:F:TL&0^[P"H6((['BI<=#)$U%Y M* VF19E8H=4 M_&N'>4IX_-()1D-IFPW JHZ')O.*$+,W$))2[IZ3!<1@U@E*4VK],@0P MV[@DT71>L0*8@R]52KU[6N8;$L?RZ29,NP<6D]@V,;!AG9FFTBMJ0'L@-RH" MY2%^H7/V*%?M8NG4L\$5O4N &K;;&"K%WF*D.^Q)D@I#,LXA396'JSHX:BAM M$P18U=G19%Y18_8&\I+)D=+[ 90$.,[\G(MM;=_8&+2V(0'MZJ TA%[! KD#@D& MF(95,RZES$-8=&]=J$B],U"F.\YKSN'9!Y;:0J7+;,$*I/,"E@YSC:>,,GD- M%H>ST1E-H_1%OCETO3,\6626V.(#,E=PH>_W@@? E,Y!)D-2AS*AL]XOOE6@ MJ7QE"VR2+K-+@=EDG82ZQB,:C,8 (O9:]0:=,RJF8I3B.+Z@(7G^A;R ;6OH M['(!V*R#H8D\(L/L#$ C%R.E1D+N#(X;'FTQ?YE'0<>TT13:Q0,R6N=#5WD$ M"& -("17H_G%U/6LLL#/%Z$ -EI%V9NP':2 >KO =-BNN?)4LC6B_2S6(GB!@-&T&I*?W#Q62O"YHL M!HD@5Q?=.;;R"Q#CZVK:?FO?4IMLE5]-5W=Z 8+)43/5179W)1.YZ&K)*B<8 M&!GJNZUUM,%4V<^5?7YT<]-0HY?5^2TTKDYHF0,SOMDP"C]ATPI?>\DB&E66?M9E>MU-.[,4.+WI8=].8MHO]#GKT M,X]24;M,E+2C^3=#IF<0 9VMGFZU6?2Z4>0% 6W.&KF),BVJBQV@,6=Q%$0R M;=N5N#CE$3:US"2R!05LL""BJ? "!]!6(R-1*42%T@$(-YQ(&(GH#/7"H4S' MRF>KE7'V;Q/; J/;< $(K/0"E$Y[.C B8!A4(E 6@E2,>W0NDF1'^*L ,H0X MP@@T#\#4T/N(%&2R$ZPLT#5?+J*TD3//++$V/P'FRME)V^\% M'X IG0>U3^9F'1__=?DW5$0Y0.":+3B6/[\Q?]DN60QDPC*J;('08K%@P2#Q M @?8ET[$-4.Y%&5:5YFR:H8-3=+VVX+ :*OH_MI.+SK>Y*@Q"-3ZV^'P?_8< M;(0Q KSL8);9G@9,)O6IH*KQ H,68XV+E5R*"JVKEQWV4]BZ>U&P=K8H6'+@J+J+$V)3'6_C*,U!I(FMJIM@]%B66?$(/4*%]@?.':4 M(6@?XR+;IDJ[5DGG>RX^&%H*Z*SEVVRS62;<-(F\X*3-62/E9I8(KYIA6:I= ML+$+HY2$F:'SB&(:1#@N4S>:[IYWAU@CIJ?Y$IX.O1\<]3/90"H+*W(LEH'[ M-)PN;KMG#W%\)G'\"V5/=$YPPB@)L_LMIF^7VO5VG[KIL%U_\ 80>X%4'X? MXST11S]0X[-XU0@,XN/8#-.C6:R"-:S,X 2DHQ MRM3N7@K/LE>4"Z_LUUW!1D)RRZ^(MYK6WA0W:CWBIM4@]-YXGG-DOU[.HAR^ MSID2CH,T>B2?<(IS?V";(;GM%SC;3.MO;IJT'F'4:A!\5[.,D>EJ<,&5T[0U M?"J67VO6\O2YIK*?O*9AL9F_II1XA(C)5TL6&XX*K3,>YEL%!25&B=\7"V)7PMIKN?.7M*-WD.6;!]@-HN'ZV6 MZYP8I1[QTN8/X*8(05E,D?;7'4#/^P3H609(N+4&J65T0+,:-PV=3]! YAK$ MQ"20]V.N68H6#-TE!*4;@L[R'P"O9J[/RG'Y*RE!(%^XR%;K-,3(+8KZFB]8 MZM)[051/DSI7*JQ^X:T"U6\]NLZJ5$W(#R_[:B++JV6#06VQ7%%XP0EH"UHJ M5W_?P%T^O]TRCH+SF&'X+DQ-8SF+7].>EL!O+_"(@J8K*&V?$B*E=,; 1TSO M^>XA#5YN. L(D4]K)>7(U76/KF>T76Y>U:0Z4;U"/6+M-7X!"O=%H$H9!Y79 MR_4-/_DPNLPPQX+[^0:+@SC;I8F<484Y^(YY:Y#EKR)Z-$#[0J(EPB/\>MB$ MOIQ0D4B%'J L&%6B'5ZW)?OLA"3\^')+5H3+=QH6Y#G]*"J[;[GRZ!%K^ZJN M=W/TB[S.0"] ?*U;Z!(P0=4"T%(^9Y87@;[(0I JI?5WVK]!3UXM)M.O=S1* MDS,<;*:,)E&B'I=;S2A1I\UL-8UQDDPJY^*$AF+O8A/Q4.EN24C(%B]C\AES MF6/\BNA79-^RGJ\A"ZQQ$N;]:7J0TT(C=;Q4;0>(B/I04%8H'X"5;^DGLD[Y MAZH536K#(A(CH50-4UEW$;*O'N7U&XBL;KH4G\3F8I/X9XD3(K;\'U!+ P04 M " "H.,Q6XG%0$H(( "59P %0 &UT86,M,C R,S V,3)?<')E+GAM M;-5=RW+;-A3==Z;_P"IK60_W%3=N1U'LCJ9)Y%I*TG:3@4A(PA@$5 "TI;\O MP(\X!05P2H%_\MDUI=(^%))Q==@9G_4Z$6S[F@VGDPZD52()8ARAB\[C'=^^_7;;R+]\^*[;C>Z)I@F%]$K'G'LX8OT3%YL);GLF'K+:A_.S[A8]8;]_J#WUYO7LWB-4]0ES.@6 MXTY5RAREJ=S@^?/GO7QO!:TAMPM!JSK.>U4X^R/KO<2!/XA$D@N9A_>:QTCE MMK=6$UD1YENW@G7-INY@V#T?G&UETJG$SQ44G.);O(S,7^W>OM84)PK':Q3_ MFQ%)3$ Q%QMC7\] >V.NFZ>..S_(6N#E92=5*-9U#<_[/PZ&IJ9G1R"UV^AF M*HEI99VH=Q3%1F")F# ?_?F\^=HN/N2KZ MZ\>\LM%"*H%B51V-H@6F>1T?->8$TOOLR)9(+O(FDLGN"J%-'EX/4R6K+7F4 MW?Z@;"G/RLT?S;F(C4QSM##FU<(M@:>XTY@/;1Z)X_B1B*L#ZX]''M?;=XGH M;9#0Q^O&:T+WS6,I>&H3L:R0.Z/F(L%"][K]_I=0'=8>JG9H>D"15NQ/$K_6' ;VBJ>(,+LG3=C S+ UL!-?FIB4ACS5C_K%^\U\-/[XCA$EKU"\ M'G,FB51Z #I=3AF>K36OZ3(/9*1'CBEG1= LT7OG:R*2''>+$ZP'-;J)?4!" M(*;>X'3QZ8)\8)*I[JO5UF;SOJ?Y2@;;FVGE[%>E7VO%7D_9G$!!QMH:*MT: ML$ OS_UYZ0@^*"?:3LD2][1SZ7OO^G_]D^!Q8[NY/JI[+%<@@ )_<7U;QV/6 MX=LA,P\"CW0,B8GCFJ)5L\(G$*#$@P T;B3G4^176,:";$S<+5H?(;U=@C]# M\@:J'ON/6[PB)I$UX>Q'C.X.Q5+$VR7TZ5V,D[Q'4T:,98C>X@T7+5X<([U= M19]N01-5C\K_F2&AL* [B/@U,%#_'P+2WT+8YXA&CZ^*FZX0#^IHH D_!F2" MC;)'%V9K3*EY>H,8Z%QHP@.=^"D@)^RT _'BZMX,(?2E"F['01&@(S\'ZDB- MO$=3;K @/-&C!@&PHP8&&O$\(",LA+U;<,42J %[*#A5"T[_$[8>U;\F,D:T MB.I:;VMYI-0 A[H00L;[.;KS8 YVDX2S8(L23&QL=T':Q&H'2$DQ2#VWER9Y-,D^<']]#'/ M])F[&_/$>7EH*0AU*(1L^1%*>/-IE"1:05G^,6P&+G<:X> G;\%XXF =D!/# MQSDQA#L10A;=RCH@)\X?Y\0YW(D0,NE6UKZ=&.N/4S'G#Y8) 58PU(40,ND6 MQKX]R*]<4W$C^#TI5I2T&5$K 74CG 3;S=VW)>4X G).5$BH!>$DV\UR,_1D U#B%];N+F0>+7W#Q"6G/FO%E=1T&E#B$/MG'TT8F;I9[2VF<<[ 9/ M80Q X!HK#\I^$$3I*,R:A(R5]Z(LCQ\M4*CB(22O3K8>U)]Q2F)B%O2\T4-5 M01!MEKX)!]4]A%35SM.#Z#<"FP: =4J0S]PSB\C%=+FT]>(N/-2$$#+5=M[^ MS9A(F6'Q6$L:2D&-"2%IA6K@HX/"<:;[S-U@N)B;ER18NJ<:"BI_" FKC:,' MN=_RN4#F;2ZS7;K@U+YNJ1$(%3V$]-3!U(/N1[$T*WX"@6H=0E[:R,YC9W*U MC=>(K;!]RDDS$JIY"'FJBZO7?GP%ZL=7C^S'0\A7;1P]REVL/S#K]1>4K)!] M;:2S 'A-6$ F.)C[6*2:+U$[H'"M/S0[88%"/0@ARW6R]:%^EA"%DR*L:\(0 MBW4&N%^M:;G=T%X*ZDD(&3!4 V]/2#Y@2O]@_('-,)*5,L4"A+H20 CO9^INB6\R2WU_+BG=/NDRPE8!Z M$4(^#.'N<8*BPN:=?>0>OT(*E5&Z++&5@%H20K8,X>YUR888ZPO9BKMG-9P MH0:$D$([F'K3?98B2E]F4HPAIM(.I-]VO4BQ6ND?\7? 'M2[7 M-;OTMQ2 ^A!";@U@[L^/[:>7+Q2K.IUF-*#!+_T(QPDK9Y_OO(EC,P.F&"RP M! F+$2X\U(H0\NQVWA[,F*HU%H>CMCP@0\$U4Z6]%-28$))MJ ;^+MT';\1P M7KF/<% +PDFKFWCZ6_*7+2B)KRE'SGSA" :5/)P" MQQB;IU!R?UX"UBCAYN;O%2RS,9)(YWJJ7NK([]S ,4!QJ60BI^J-5:7#N M1:]&4U=YI_>6>\PO\S]4]);_ %!+ P04 " "H.,Q6,SB*\*$G /OP M$@ '1M,C,Q.#,V,F0Q7SAK+FAT;>U]^5/;RK+P[U3Q/\S'??<5J=C&"Q @ M":^,,8D)V!S;9#EUJBA9&ML*LJ1H\<)?_W7WS&BQ9;/$X9!S[[OOWF!IEI[N MGMYG].[_IB.+C;GGFX[]?JM4*&XQ;NN.8=J#]UMAT,\?;/W?\>;&NV$ [:"M M[;_?&@:!>[2S,YE,"I-*P?$&.Z7#P\.=*;;9$HV.IIGMRL5B:>?KY45''_*1 MEC=M/]!LG4>=+-.^73X^OHV:]CS+3#7%)VJ2RL["T/#6B#LD&^_OB)>IID%F MTSW1-%!-3=_9+9?>K()#M(@Z3)>U+2',L$+^]:1]$3YWIJ(/A=&#CC>\-90O:-Q\L92 &MYX MCL7]S#[T)J.3$7CY8.9R/QLL>+V#K[%G$7N6HYZZ$]J!-\M>N7Q)$ZH.OA,N:VH@?L:DQ?DKWO=T;#GP,JX'_K]N SUD- M$.5I5L,V^/03G]T40=8=E/?W]]\\9MS#Q+C5$;<-^&]P9FF#F[YF^?P10[UY M<]-IW?SU5[/;_ J#Z4-S5W/-?M_R 3!X4"H$HT+@N*YFC[CGF9:%N/RKJ@?F MF)\[/?^O4^X&9R;L$&AMHHQ@!_#7)U9S4&&P+A^YEA9P_Z_7KU_#BW:KU45L M6!QAAK_@\5^GCA[BSX8=B98+D#B-@(_\ L#I/V)%^R? 1Z,\XIPG(EQZHL@+1T\)YCS)@?S"S^?JL/V^N( ME8INP+KF")HT^82UG9%FY\2#' #@F7W:R(8Y5OT,TP?,SXZ8[=B<7IK3(]R1 MW,.M3K],P^ V;7S\"0V;0 ?/U,6>G@9ME+EGGC-"[L\7]_.EFX:^*9OU^:34>= $B _0D!K;Y8^]3TMXY1]Q[](K2]V\F$,+FZG>SE_6S2!?*/N.:''C^6 M!NP1M%&#J5?I*7"T)>,+:WCI%!()U.C)<\16]\(\8"$#WRWB%ON2Q:@%CK?( M=H_ P3R,6:,F)CWEMC,R[?NFO1\O\_-F#:S>I["P@%!IPB8,5F$_*^?AW0[T MAW_Q/^]E^#UZ:'G?O /_KY1<.R))_F]B!3NI)3P!A0]U"!4*:#A6 M?,MPT^MVH]NH M=UBU>B[5FK?^:YFDUS$J,1A\93"1_F\"KM@&.]&CR)=</5E/=/ M)N""_K2SGIQOZ_@@_VG>4W^W@Y >_X/P#VS>KC>[K%V_:K6[_Z"%786>'X+] MQ ('.NH8LF.E"G.\^-?>MO&*.?W-C6#(\6GHF8$),]>G^E"S0?Q5]0#>L])A M9?>?@ADTPG!-;>XZ7L"VU6^N@8+E?L#X&%IN;GCTGANOCN[=G5=DPM6%@9>] M32WWV_?.^+3O:'M/WJ8B\OI^RYP&1P9:S]!O:&BS&8#.[:QMG )LZ_@\M#DK ME7,,1UVZL_].$N^NB_D%R>3@U,;@NN-1X/J(A398"Y@QVSJ>I^T;25L1+&WS M@>EC1BW X'$V:;M.I7_E[/5WO[Q9@P3.FG?K^)(;7:X/83]&61-6 "?(>6YI$Q", M2_=&8"PB6W)&A.U2PB7)1'#,95G#/0/M=E.TPS0?++3'O25JJ%J_NG;/#LN: MOC99%<^)$:12OG)X4%JN7?X96#],8;VK31LR4*83-ZXB@5/]H87NZ,O9]Z?O ME7D2+ $ +/B]?*58/#S8/UQ%$/@?[\GR:;XA..A+= 3M4;0_'3 W/?8=K$W? M,(4IZO3?]3R1GC.3^_I5-HD7QW_+,@!9S2E\&;(U" MN] IL/K(M9P9]P0:69H=6-,IO)HC]0[IP^/GU[Y);3NOC1\-2$+%KE#%D?9] MO+!X(#4C2'8/ 1 ET$2HJU#>0X&F'GI"V,P_MG@_>KHH<&HI@5,U#(_[OOP' M"S%*V<*F=W%9.[_J6JUZ:6W")F/RK>/=@\V-2\T%$E?!?0J7:=T<4]M\?H&5 MK 76X,^6UW4F=O;RZI]=_\]F?U4BO+(4G^ MM;PKL&E QBTQIM/TUUN0!=+_N'P3:_Y8SA<-]53LX.% MMG]0*?ZL,4#JZS[^>" *MR6Z'C"FZ6H6XU.NAUC!!H]!BW%_B;)]VIRK MN.^)JP $,\3P4C7[N\?-XI#$__[KH%QZ\]:'9A9WAX[-F4T&40YM-RM$]&UN M@.NE >\:@#:V/;]/2G*?H)2M0L/E.\,XL[Y>?NKU] ]KV!C)Z;:.#XL'2S;" MJP6!KO3OA0/;X K7O,K&Y^63@X96J5GA.K;S_)Q;QY7#$K0Y6 ;^/R%,^^ M7M,)6-7%F@#<:,^#@>TSQP.,RWB71[$+[@'/"U$&^Z#/1 0=Q KJ6F9I?L!$ M2/F9PUY/F"0Y*BK%*%.[*G4+YL20@Z+&5(+FNIX#PAS]O9XS93UN.1-$"KY$ MW+&#_"?6-X&" V;Z(#8"#A0U,%7AFZ/0"C2;.Z%OS9@/%/?[,^HI.S@] $WX M-= >7R3BC<090 E[A@J%>H$3X$RP(T:33/3B_*-UT\"TT>%"I;%GVK^-\Z,B M(0?N=&['D=+K:R/3FAVQ+P A0NDO&CPJ%?+%,P.@(3K*H2V]3C];.(Y;I<.@ M]^/ZM'*[EE1(SW$L#J3W0IZ4FID0$67*2)G5 ?.D8;"(F(?5>DL 8$U)")B; M2,MAG0';+>\)KF5S63A,OFV7WK#:69L!\@K0\-4R2RT!;I9QDWRXI-N3R*_4 M8L>AFBQH= E['C:^M23X975/.U^&066OOT[:4U%YDOB+\(@]>? LE(]G!UDA MIE\D>VE7@^4D*)]*ND9TWRT61,N72OHKC^,>PTIZJAQ 0>ZU^OUEMM'T7"^/ MRN99O__T$/1#6& Y7,_)"@!%7D^ <:\T*.T:^?)V[]7#&$.T_4U8H^'[(??N M99#22>M ]S^>N.'@.1ED ;J7S285GM_=UA_&)K+M$C997R"8,N^*IWY9SADM M4I"QL9X4UA_WP'YTLVI><(ML;DAK$)"S=N/O/S?R/1=ZV]O]=X8=^; M *S3 MQ>.LHA9''S(="\,%'_U$[O"9@X^E97/^!%8\3414"%(9/N_,1CW'VL:PV.^% MH$IQ[0C"$AD!IF(=KD0A;'^9$)L,37@1BXIYO&6%/7NPM('G@(C%G>5X1\P; M]+;+Q=U.:=*<%%'1O,AZ M& BEZG_\09.S*BER!\D,\S/--K!5/D 05)<8"B;!>)3%L98L\IIX\4#RHA19 M0DB]8$8\<*]L]]"J-!O62V?$%$K%<<[KWX9/NF!XS?-*<4YN*?-U::'ERV"9 M/_9^6-6I=O#Q[#'1JV=DF?DZ.M2%BR5T65C? DWJ&]J/)6S%" YVJ7FW/& 7 M%[7'J\\O0S/@+T!GGJQ=9T9M%H^YWMR-=[5IL6R6O!^/20<][.#P2EV5I81R MS-4\-M:LD+/_*1;PS"=S\7#H<%6QY$N3*/,4W5^OYEE)SBO+^GXZW?O:TY\H M AY&S@R)_]N0)TO@5W^)P%])J?KUMPOC=.!??EH_H5ZRG'V!;LHO%+GSWL7@ M[JI4MDZZMS\I;1_A%,BFRB^8#!VPYB?B(=:R>+KIDX7?Q_+7^_P$.8H6@,.@ M>G,LCM&IR_^42H6]XC] :)=_D=">8PCM>L3K;H__:3^FI.XQ#)$AJK_\-E3) MDM7SNW7-LGJ.0/O-TL J[OF-06^M!/J[1?0Z2ZRE9)\("_J7EN"( 'O#-C#] MP%EOQG2J[( NMP I^K]N;(+TR=9!5@:8#0$U-$D&&YN@%1SL11#\YG!^Z8M MSH")M'=Q3U5HS.6\Q8'3"MO&5;YY2ZEOU=BDTV,NGA[#PAN1"RGW\N6,L11! M-S<2QUBC43$Q$G=,C%M8&UI_,9VHC'55W<8]&[^^A%H*:,'2#T\ /C)+6$W5 MRBI@/A L-0%)=H+PVT70!R0JX'EI&LMY:M&?9]D_FID8_ M*0$V-P13,'X,-!;7J_,?MP>3 MVEK.72Y-E2^#ZF$I\C5S[=JWP=]\C4TB=Y:96TM<<[.^:VS6A?O$=#C16^CU M(\0J!AC\+6NY5+YPA*.K742@D(F[B)6E2<4DSDOE#*3OTZ&IK%MZ[BG@5TH4 M%J3N3%H SN/:;;['8:? $"XM,PG0?@8\".02@)(X3$V9)%W$>.NBV/KW3.\8 M;_]E;PK%$FOS06B)DMRS4W9J^KKEX+U7A;76@?RJ^I*MXQ8>D1R+R^I*);H@ MHYQC]]RZD&,:4Z?,6>+,ZN;&-AZ10/O@H47L(K@GI25T+;U]E6/DUI'%#$H( MQJD./"ZJ@S"/>&5I>&P6@/0&>/0"M*8V$MHQJ;R"H1: A^@%FHF'5ST_8-&- MO/@^&A1KIA='Q7M&#%9U/=-BN^+BD!Q-GQH7]K8#S[('SH16C'NIS4"KBF'9 M=KR"G+B1YM%8I,'CF151@3H,]GMPT^^8&3+\ (T[8] +N MT77DIIU+X!^(8ED,S4:NS#;)\A$6MI_.#/-KV]R@.:*A04B-S3$:@3B'A H9 M\3ZB"T*E!I/GHAA>P1_,&/0W\'YUC^M<3"$O$)PHSVIZ$ 2VT)V#FI/2%G?,DF)FB8U/5+ M"P2L# M5;OHU<"*5"??LC$4-9CEBR7@8& &C$T">D)C1DY8..8$' A\0(O8(18)!_Q( M!;A:/F -0*1B3'(7@.$ZL"0>S$1 7 ZI)A+:H6K;(3R\Y!Q=M@+#J&4*04)_ M9>$&]D\_]&S3'\)R4 "A.L7PT-#LF0$[/"R4B Z)!T D&-OE]!$%:_:"0T(B M?FO&GV7 !O%LR+K+'$L<^FB-S?$JJ%?C"M"Z%"#_8A^..Q)+#F(MV3?!/Z0 M6X](#WH#4"XD7.0T'ZR(S"7OETM:,&!!/44F)8==4&KJWI$)YE*D.D/FMTRM M9UH"+E5,#>SI"_AS2Y$ 77L\<5D)0@UR./JL@-!A\;&U2.XG2K:O\>:.[.AG MRJ![$C;2X\[A ]$!@VYN)'&&3#_0/,.2Q[$Q^@5J$-_)-[3F-1L/#FI+EB!94N\J;,SIA , M",U/\SEM[A>]G?'R.O.X1D3Q"?1J++D;Z?77'-N6^XSD;*=>PPMJ 'O=LSU MWONF %/K7?OP#;(44LM9:=/@"5,'0WJ9ML3F!FTU$E'Q8//[33"&W ")2WZ> MMM_J\RX!VK):%[E MM\#.R0G%((=@Y@@5!R46$Q)/ZSEAL)IBA,D4U03:D#$,%J(_@F458""2'4G' M@I8SB^@[Y!9Q+IUJ'_/'L,S3! G>EQG;NO->E11MR(J:Y3LDX^2TAKSWU8]% M'JH$H=45!;-YAL9,+3Y>C4F!*!\Q""ZIC^XG4!*5MDBJ &X\KAF2W-I8,RWT M'7(+6V-=;)78593DT53@R4>[Q@]=5WR\S!== B<'=-0UF4::_3RO%=B7Q:5N M;E".VR367K$@)3='&FDGP%X&\H4!AL$#QS,H7":Y$>@ ,PH#'<4><#:=/T@+ MA,V-I^T,8IDT_[UL:^D!B8CRL^<R*D3H\D[ A8'$ .A+Q+ M2MFT9L* GZ_BOZ1Q_%6&SJ+R3F-4X1''2#53#GE222854JKQO19\"8/*9$1/ M4&I[)K""AJ'C.><#J>@D\DR5(D4"BTE//Y>>6P:]YMSH4A$OSY$6;]_T,5B& M=\"#9471@E.NRQFB3%8V*)>:!U"7R^F\SC*5#5:B$U=A!"),@M1.!C<4Z)L; M"C1:L/)>EC%22G1$ MK#*;]PWG9"BL*/0&0NSI\*L?XBY#RU/""N(5;[WU,))\CU$9&[<8/AYKF/^, MK6=B;8611=Z0ABZ9DF!7.B.>M 1_WM),"]JU:[JUZ[M[-(%")!7 ^VD5NA[ M'!.8KE!+(@OU((K%=)*(I5O$5N!VD9>"H>>$ T'0">_Y9D#FN'0T*)"KY"1R M0ORAO )L,@FQV!T1+!DB5@8B&&8X8/UBW20".3GX^!V$ 7G!0G&)#321]T9Y M:,#Z(N5Z3R4" KE[P)(7\.98=&MMCM6ZC.[]?-&F?*/YN=[I7N*W>!I-5FU^ M8XEO4)W6.[5VXZ1^RC[6VW5X_[':8[WCHC:/!%M0;KJ-:^ M$0RG]3^NZ6_1J='$#T!5NPT8OM9J=JN-9K3( H'2KE^UZQU BVC4;5$_;-NN M OP- )@!;BX;S>H%P=#LU%\TH865#YIW CHU?^$XM\CXL;Y^^2;^6[9XYNI? M9W7\#^;C5F= I- "*:]*)50^36+$DAB)Q*"ODFPH7:1:'G'-EO<.4&0;5#1( M%D(BR")N4-(F88-9VL1/F#%I6PULJ(4BABG*79(N@(2AXPJSQC)YWT>+U0]' MKGQ)MS>*J@2,OJ"^![W/_3FKJ1\&8624P$-1CH/RV3)'TA@"4SI>==S_B&V; MKVB0P+%@992PHZ10YS1?*I90YH=^9!3-KP5^-[4Q&G2B46?F8\[H*04S,,YB M2BX;?-\:L4N\E:;JS-#N6UG0-/&\%JQK "5_HB0^[3<;HE6T8E M+L%"I%AE]"5;JI:9.%CM31X%0"CY (P'$7;@.;7AY!OB^_'"8PECQO/0,N8? M@BHW1XFQ-S?4"UKZ?'-Q)>K\4_0VYA]A >O\0]<""3;_S/%]$RW4A>>2:1<@ M ^; [W,L=/"<[QD0^\.L96/N9Q%SDZRF:">J1\(O +E@:1XR![*IDC 4*N!X M ^PX\3F1L8;WS8HV?4':F!L4OR3X ]T)N4 AQN2R:(38V/03;J2P)J4(G$7@"]:8-%!J@*8*/4"700=%GL+OQYDKND4&-6QA:BW %#A=:08[N M^4Z64WBF?RMVIWU#_O&R#Y %!Y,I_@\B_11!YI6EVB34D6+6*OBI):29\ M=.B*6E+/B-J8I4HJ&73L M@6C!34C&$ 4YCM"R$(8%[BHA:I8&?##>*NMJZ!P4ER$UC8'>X0 N8,X6$@@E MEF6IU#\E$@W0UCZVTLB,D.$3<>!<)!SCD%1D5+YED>7S5 #G<_4]U5-/]#2X M9J %)DK\TH967S,M%,=Q7('.S ?B>_/*/%XY[%MITY"1&@^7O'D\4 B8P^IR%]4=#Q?>QW=:SDR;7,4CH"?_:$,K29N/D>^ M!^'.I3Y:0+L;]BQ33\T9AX.I@-D-DL7= P?XQ49P-4OH:D^< '&PMEBND/AC M+/!*6ET"-:@F?47N7>A'( V,X2]& M,>>Q#*!)R!Q=Z%1AH"*B2+/GF+I"4!D8NNGIX0C/"NI<'G\@"3) E>IA5:&L MY!#+T%+DR9I?;9T8O<"ZH2V#P]R0)2$D9C1; "'PA@8RM-4LF,H6=E"B.#P) M'"52L")1%KXOPQ_!(P$2GH3B3UE:++,> $F&6Q]MHKGD1KS]DJ"@T/0A.&JD9$-=1S3"_*": MHSIU]"S5WP'J<5_)F!XG09F.4<=2#72/%&LYQDTAG!+*%:Q_TX]UJRA#B8QB M9*&D"D'>41X,= :# ;^>.[_&!+'I;F@/:6'><:%_M.B;)QG(((J,8[3)U86V M6I]R7?%O/*FM8B18>T:]I73$8Y.1)!!?-Z$A!(_(RCO9%UE#1"CH RB2 B)+ M(ZTI650N*ZFB@RN)M23U2 C&E>#>G%P 528#^F+QHG:W!112+K980 ;7)#": M@BZ%7J)6!G\1U+P#CC,!TUJJA$1,9299!RY=V-,."X& M4D([VF,D$G0Z$S2GC3.5+NJ>Z3C#,5!S">M(Q0QAKX.ETC<#?[5EY"6'4!(+ M][,CKF)(64&$%!&!IGLMYN+NRJ^8+VJ.ATU8]$D'X*V(O$ZE7)"9\.S0371S M!UCYPN4%E4>8PW_O*=I(^C[H*,=G7V30KXV&W)EPR57P3YZ]4?6>LB)H/F=! M,&>5\HAR9F0[<:0-C2.DB7+\90DTGP)H/I8_O_0,^^J81M+>$TC!=*="C-HE MPG?6U+<6J5V<,U]&^H0GD0J4R."GV'F"71\<(B%AHV(D2K0L#9$4V-GR&#\P MO 9NI6W-9,$L:1VJE<7B"PQ-XHG) K"G)LIJ\E^,:\O/9XBX;''UE!B0..B<"M@@67HF3*)+(2<$.&GHL^B6/RA58 M\^?7.1"KI8O _-"+/6AI22LMIP:79TN$-2_445)CO.Q@,F6WFPZCC\C@JGZW M\M7[$MCQ:4B,@0G/E]'U#KA@M*VY96%F8*'.+=FH%\Z(A:C$';]\8XAF(M8# M[J,O+/'8AT=-DQ]=OX1-E(.5NS)M9-B MHI(FV@!]O-$B#907G>))N. "@LV->1!$'#90AX"6C$4Y,YPTM,%>!O<# [3" MG! >=D(#P^,?(*?C#\#'>C>&9W.#[&Z5+4M"I0YRICY#A(H3BW(]4Y>A6^C_ M5A[OB865/)<0'?L21"7BH09!CPCI1364T"4GQ%\*)Q/"+T&5&D8.$6&"TLB8 M3\=SO/B55(1(B$CE1Z#\$FB5\9$$/00Q>T))8$I-YR[%7[&X0A[ 2%2@R3-# M$ML_0M.3:BAYW+F8?:GARQ99#\A_[?XW__5;Y+_BBYD.\6*FL^B^NTXB]1V? MA_;7?4/3+[VB\#NX^F#+;AUO&Z^B%?PZX%_&E[N6W0,L^#GC:N^Y/=F;WY-R M_H.L;W4][+;'A3O5B.O4$7OUC:JF4[CWZU31AZ@>]=&I94LZ+*Y[3:=TTM<5 MIMM3OABU[),7V7>M:VSHX86-P:A<*1U4]LM&Z89/#P_SI<(P&*US;7@Q0K0: M;0EUEK'<8ZZK5GV><6U470>6*]T+H^X:2]V^4YA?^K,2L_P+B%E^(<1<^]HZ MCCR,BC?Z7&'T[D'$6_89NON)ND;82\7=Q]_WGJGPU@=3#5/W9-ZQ!B:'->&R MG^*=4'@3!=O&PV.&(0\SR !-P\9*"?;UI'T1G7EX5?CUUYYG(N-Y;(R'6,5[ M_[6*?X55O(PBS_!UV>AC"KWC3N-#L]J];M=?MHD,^BYUW^>BOB62 MRG/7._8!8:+D%0-T/0[>=%]E="G>(!N@,Q_B95@T MG$Q\WG'C%_K$OYGEGJT/8#P4K^^W*FLV:N\Y3?800W<-2_J9CX\_=M&G: (> MI6W E7[)4L-G;2"=S(ZR(8AP5-Y:HD\6W)]?#^V.O\-J0P^$@^-BQ+Y68*=\ MPF<_S2=SCN!>\1Y/4+5[>+/U(0&_#+.$:.EI=]?KA_X2Q&>B+_OA^E9"G\O* M1N$Z11S>GV?R/F@Z=:=&2]P%(=(OO]9H_9L"M/N)Z_8O-#]X.9;I\P5/=WJ. M,4,:[H 3:AVG$=;AL!K:PFQJ3-^RQBG]<5,\.+F)"L9] 1SUX^>SS[?-LU;U M>_V/=N]UM;_WW;\L?GHS/?_NE]^X)]\&?TQK^Y_.#[2/_MWMQ6EP"ZL;GY_O M_/@3D MJW96.6L<7GWHFY5IHUR\&WP/=L>Z?G$YM(L?C/!D;Q:,V[6@71Y-[YR:/9G6 M>^YPLGM7_+-R>_FZ\S6H7A2=LG_=]=TOP]K^<&B<\ME5N_;UZLEG9?VU9QU;X^KLUM;0?^Y<6#[ZVRQ>??@0]\/DOM:_\[CS[@9(4)(=SVYF+W'MU=6.)9% H[O1_?0+D*,/-^?AP.1L-_=2FM:=HKBW1:ZIRG=LOY=\QU MDYM1F%2%^F@F6HTBH],(HU[ENL!#A1K$L2E-EH:).@G+L-N99+D:G?3V]_;5 MB4[,4N\?G5Y>W#B.C,/HTS3/ MJC3N15F2Y6_5WQ(?0!5-$HOX\FP.V5R?7?8@P2@QJ8G F3(W^%^3QOA4DOP] MZM"(*BDA;).J>19724AZH;()BZ2LYI#?W$1YIM.ER;-T#B)5F,8JUE&N M(;Y812:/^+UTVNW(&R<7 [43E?C/KDKT4B>%\,Y*Z!O<:M^].QE>_#*\YK4? M?S@['OQ\&:C_K5*M]E\%BO7Q11J'Q>SPB8I\=%MOTVZGM4^/1K=7[U[D>HHE MT)_J+(WZP='+6[NPG7I[@]4DIN-LO@C3U6X ZE26TCS3E8KD6Y(L/;3(,XQ= MD&BG&62E%M4X,1%^ W73F8(:C:O"I/0,7AV;5%0!^I(68<1_[]! []U3Q\U3 MNV(&SG5\HZ.9&D2_5:9@$X.G\D66RU@[%V$1A[^]5>.>QSKXFT"5 M61RNNITP3<&R"-H5-J;J:@9]4YY^D_)C76S4Z%&Q(X,YY!>!$Z,,#"U7M.)C M]\JEX\X.&9)=M<60J#+\Q/Q)PDAW.V#?\0SO3K- G248)S/0$=YQ+/Y7O1]$ M_GWUI17\S_"!3])-IV O\N*W*CN$3HG*L 2ZG7WV)$65Z]XP#<<)>'^MIR*D ML_F\2K->PV=GEB#NB^.;O==O#KY_]>K-;B/%HJSB%3N*BAW%W#D*5BEV1F2M MG+?8N3W_>+ZK#'8-OTET0=@F7>JB--/0*DN4A*2B4*@DZ27FDX:IB_2BS/+> M&P5AIJ8H ^OS E@SY_1,"H5?A@69M#Q9D1-JQUY<%?1AIGZ.]6.5-"F;'SK.D]/\FKJW/'*V>T=,N*[SGQ#M<-X;F@Q MLL7ZW4[M!TRA]!*$LVF&:/&*)H.![Z';)3@^5^$")(38@K1AS!P?EEK,A<[I M@1";D&8I>$DP%]%,1Y\6T(82K&(XF.4%V9@%IF%P06+K=DA*SVA'O$ABDM@- M.+-F=<8P5R=Y7_TUQ%P:-A"$A+]C*K$1YZ2&/^M4YU#*]X1TPSE9*C(_4,E) MHJ.2&)_E90B>UKL"DICFUEYG55X;OUJZXMS)'8TKD\1X,(7[%4,_-ZQQ3&FN M$_'3D-$ RI8$+W)>BRI"$ZM1"?\,$T<+*'\/U/E)H$X'QZ. K)Z>D$D7PSF9 M ,_E1+K;#WUEN?)WK<(<$]N)REE8=CL63F)6WYOPGGY$F>@9@1=N0_(;LI/4 M70CUTDE"NQH,9?;SE/262K([<$6')8,4K)L>@)6 +#(XRS#&@. AK1<_XT?B M[?=_X?E\'&3(A&D "DQ$CF\9UF1A%14)\I-)0( \HN^QI6G?]Q48D639)S)F M=V$.3F0 54L2!9:886NR$%\IHLSNQ)4.+K 3! M)&R0:[F*_5L;OEIW7OH8CC5S B\M6UO6BUX-CL4O(6YBC+X;DT,9.5W MV)=VAH4';"GUE&&!U3+FY*.>HHERR/RVP3-;OQDVMHK)8 O>=7+@\0.B,6&[ MVNWP0Q \5J!+;'ZR]2JQ";3@ C35Z4/9/V9A5F:FT'MY5U@/M.D"C 3.;Z2 M*,^"#]]>"O!@E05KQ27?\!X@R&6%SBXFS@K=TP4L/0L6@LEF,"N%)]$=Q#FO M \+J/ZGY=%>%209%PT>>T1G-;1:]KP:R]WA/1E6938!;>.SS<%4'4($Z>.-I M.);:[>@45BT1NRS;SW=_@YJN2U*3^>[G9HA ML9Y#5TOQ^"'4%S^0EPP3(/0"X;^94,17-KZ8C24(6\P8>&WQVZ"<-'AJ56AI M8FVQ;I/:P'!DJ'A#X =]/PNK@@T?5OL):,**JA"T $2$4)W?9R4 M"E_B9Z<74]:;LX^]_9^(E")CPXA-1R;2(22[K1H8 H#?9.^25>!1:ST/".74 MB_O,>IN-0 M."O+;/Y6_4#?C;,\Q."E^FT;4G@H"O. MEA5L,SB?P$ J3(18QCJM'"KOC<'USSTX6::&0<"NV(>32_H:,P'=AW-R!:^" M@UYLLOO55-.3/3R)O[3=[X$S(^SA9BN$#R"6TB4,@:TS;^*KI0DMJ(4KAA/% MLL(EJ*6MOP8FK>VH(1H3Z$P56:-O8[\^2<*72W(<0!@U;D$T1>-,.:X7 +T6 MC -0E2:M0 O0KPL]A(F4#.. -TRG!,'))$=1E7/LL (6N9L>PB@7F!P12M:D)F=:: B^$BX,;'2>*H->@@4!LK%U6&Q'D?W;!RM M'@ZCGY'4Z_P..TUQRII2-&# A.(5F_>QT8_LL1/:=]F"N 4EN&%XIRO DT+U M;#[48CYUE1&$5R>FB*I" ].ZL$Z MQ_MW \YEU%4+-FMEP87%C("+JRAT.\?KJ2);(?C"9;?'B/U3ZK2/34A3U;RQ M(>)F#:?4TUP2N::E46(I3)%7BY+B%6O85ZH$VU(9!=:(JSB4T!7#U2 V0*XP M-M,Y([:V:6AL/&@@4T0!)[NRHO_OX,V_3T?7,_Q^6GXC5=[MA'%,80$99G&0 M\:J85*G4R.J,RU;&4>PN^5 6)<4VE _:)K4FK+;"%ILB$7Q3.JSI(UW)#5'5 M5..?6(I<*SA:ZPY:]Z"1I;NTG,$!9C6"N:L:%O9*_MBMV-$'N1$"]\(0G]*"9,D M9]_JL7BPOD,BXV0'4:L18LZRNY2HRS I-$"W ">7*:BF1 R1,F^[R.]^9YY. MV/$3?P4?_'#WH]OOC]X?NHG8IB>NU[:Y3-N"=4X"=-/ M4M2IS3*!30F'!;I8YT/Y<U0J]/'5*RDW>2>TMPA1\5SV!2@0R=:0D]40^!B MPB2+*I?'!]72[>#!<)/&,-[YBCO!Z)E;N'=-C1/<4TF[@O$Y 5E* [ #JP#" M:,JO-V)_6M[ZU7_RUM]*WOK]NV.77(1*>AW>B.*HD[=SVQ\A6-11E;-I M8);56!$(=VXD*[?C(68PJ@;)C.ET7H;4+N310CETFI5L9<*MM^XI*FG5271F M>EXEL!#=#G6^J@E7C6NT3;]3Z]:T"?S88$E##P)H"OA'O==JYY0:2RZROCHX M..B]^N'-_L%/NP^"_FM_P)$;T*T*#E^B2\&CQ!8"'?>K9NZ7^,SKJ*1Z3Z1S MY.[0/+;;S$6T_HL6J\@2WH7'"9ATYIT$6%-38_" M=BZWDNR60XZ5G&-G_"]$9'"DMKH2)JYI !#-Z2O">68GM+1JYMT>HMT\2!'% M-Z2L*SADZ[J7^K$7UB,5EC&UX6[1#JI.A!SP$=NT2:D)"EO1V"Q/E'#VIY[7 MG3:!Y@>B378$K\'-WVE-?]SV[+'K3&I+3=BVY"IVM9 4/F$5:?Q>4\.VLLBK M,W@#3DTMFE;9IZI,RYA([.YZSMT6[,N6(LWBX@.9!0H+HXK_MX+C!G*QNELXZ P:HV&;2ON)98;M086 M+H/E59+G.DRM4=N,6B8ZYKZHQJ6H)+PK/&O2,H30Q+422;,UJ4I*1=?&0\K@M%43A'\R5> M MNGG];;>S8W8EO<>=X1OMJ-O:(P.U8^Q;K1[KQZI!?G(>>TSS48VFY[7;X0X* M:9]M=T_X5E$Z8RUNX7Z0X//-%4PNZ/7Z":CGP(+^]=?A@(IV5UN[;8"'WS'+ M7>4+DL&3;6/@,U!T"B& MY56!,T&AU6Q8:&"Y!4:H3R?87UBCEAM?NU:+S>^K)%[_DJH^? M9WW=& 5.>>,KZJ);_W*1P#:L?YW6U[E!R7^XH;Q%W*I>F!K,\;IIIJ:$M.N(C;68:YL1I$AX5(N(T^ M.(WQ-(03/K) ,1%V63Q"@TV:-Z#.[+2MC>#FDT)"#QJK/@5"A&127FOLCSOZ M!'()[WKZN#UV9 )L7:/*QPR@E\_25MXP\U4.> M<\X1O*$2*V]O)6A/V$5%9SF%D>6^F6((%!L.I&CO4[8;!HG/9,%Z4P.3*#;I M34Y ,;$&BK7W8>OFVW$$LBQ(]D^$VB"2CZF,G6[&;2Q>,M60,M#V! M%"H8+ URP<14%)<4G=K1)$+G $$:LQ6-O0H=6-2*;V\X>-T_MG"5R/ MJ;!BYZ;>%\*X1@HW)85TFILC^G M%O&P@#><4]H8FN=:XDGQ82&TM6,;?+<'N/TY@SH<\/KI70IJ2CT"J6U38QN_ MK6!Y**A >A:B3Q*JP$AB,U![]DK9(Z62>:,S3/EB<=M"%&L4<(+!QJ'!-?3C#'[DU=CXF8D"G9 M9>J6<2D764;8$L^V^=W>:=@+W:U2FXPB8\(FA^U,*)T[2OA&T K/A@FF2L5_ M^L5FCS@.R2=\_N71^CO38PD2E.D4U+4O2+X0%% N,(U6CRD]26/=B8WK^%A2 M5%##F5E S0#W;3N:,[]R$M4.6R- (?'I!L=VLA6UXR4T92&!3.D M:D55<@N,58D$,"61>P\T]VG+W#9MAPBK-"5G(L,IQ5M>.@Y)_#&J@7V_-.353FNAKXW@0:$:QTD!^C.(:#$CZ14M*I MI13*SH>C%E!*/B7#_!-V-%:11\-P5=HT?'M#BY:;^1A[6/3(/P,XV0P)B=/4 M^EX Q-+(&/J!)^BP>6QBCD3)4H31#!B?W6P5\245=)X<6\R5PBDH:97%"V=D MI&6+:6^\26/6X'VL70N4-F*=//<*V&B*QKM*@JEN^" =\IT(*8^#OI3".3 4,A!FPUFL$26#=OLZJK4K<]%/?0WP-*=ZTZC M+#&_;!QM4==B+TMKBWY)7V&Y=5V% M]9821#A=D05^=G%"[>/D^O*:5-0/ZBDUUY#6M)I[S$4:=OS')R#/0@!12N#B M\;A,;PDDR^A")A"3T9$RFE<48L:-AK?*&@+"7EX5]M8H\T7!3RY M_4Z\3V9?UKR\QDDZ&RY\8TJ7&^Z(PAZ19RT==K@!::(&+"W]<+R5*9(CZ]*R M)*'!9T$U-_1)\+VRBF/W;L.)C,\N56F]Q]@D1%E1%NON>*O3)=]SO]P2&KBY M!!ZY=!/V.J#*Q(C<'X9&N3^$LUBTGS/NAPE;,(B9PAV'B=S2T$Z&NLABO?S8 M#.M!>C\".)2DW;VU"R*4!Q( ]?FCV%X/1BZ/.6?F^G.52C_ZH5"YZ9YTA61" MTV!S\I\7F6VFQ>5J^JE4X876G.JU5^3H;+@;0@C-7BFVN14!+T2(U=0I8^FY/ANGDRN29"< MB_/9?&$%N5VAQN1^8C;7S7F^);55L*46+)F-$WM41$Y=9I([YM( $5DM>&%9 MSMU%4GU^M"S2Y*&]A"Z1E4+_O/)T4&,=D6I09S/N#!V)O_B7U\G9#UM=I^,? M37+$QD@6OWBG'+BN+7&: T?"WP3IOAI)Z'>O[NB.P@8'-@4U\CK,Y*B\S-9 M+$O9+UTX\-)2GFXG-H""[(,Y"+C74275'[D2#%0(/JB;VH*F-4K/ZW,:"\?8 MM&SN-WJ@A^NQ3AQNQ'WZ$94S/O7EJ+>IE57=>D:4VK0!]P['NI36#;]AI%VG M3L.YNT7)-<_4"]J.'M=6TV:H8^,Z6-J*DGQLUD96GVT6W'?% [K( T$LW3/ M/F&S]= _\W2PQ^>1]J0.Y9H*6X32D2B997^O]]>@2?EOQY= >@+@.>5?BN4A M>?!J'TF&<6U=4E2QJ$:W7.!QF2ZIUU.3*-]D)-T[ M]EX^*2EZ/2=TDZ@DF#''Y1TB;TJ'UCQ^O867?;__EJ7D:9)KN+J;4;BZVK*1 MFDWT1[:/W#SX8"N;X?N=GK:!V&G;AM#/=#BR-CL6;B3SG]0_Q9FIN9P@H 4[ M#/&0(GUF<[M0O&WDL* JGXI=BO!)=$Q7;2X M)/#6=.JU6F,W=<,VU3$V&FM.77M-9[:KC?.&_V1;6\L2/AN_];C0J69B3Q:V ML\(3NF,KRA;6OSQ9KHTX+?OE$/[#$G JY\$G=_J6)KW38SI!7.>GFH0J=WU# M8>[N^E@5'S_\=+#WC%3N MXI?AZ.9\B$?/+M3@XE=B^.WUVH@'/@Q&ZN+R M1KT?#O'TU=7UY2_X\?):G9R-ZH_O?U4W'X8L.?Q"8U[B\[6Z'OY\^W%P:[Z]&HQ&&.GVZO("8W0[PXN3RVOZA@8^'^*9D;H\ MY4^7IZ?X?/$S?;@>XDL,2-\/CK&.P?&O3,/)\&^W_+>\GE]/K@YP_#' M8-/@[*)>8Y])N1Y>70]'8(L\='-)[W4[]/#U LX \4*O#D_NQA\9!HN1L-O M0BV>D+EY_9_,S;/*W"#XNY6#C/2/8CRK4.]FYB[?K/OM;9:6+@9S%[,R;'0= M=!S:I+9.14B=/Q19E4=TEO+"3Q6D7C683UX9X%CI.2@!K>B*76ZW8[A.K1LA MM2+D=4^1M!A8'^<[U!9EFT0,TI4KZ-CK?EW)Q>OF,^DR2SC?H=**0QKJ#VA2 M\E(FF9I680Y_#T\:%JX"X:^%4U5-"<@VN-:S]-5IE=.8 M 0WF)V3DH@'*BWDCTP4<&==]6[SQR>8W;-NOK34]Q%O7$>%W6?)A6;KA@QH0 M;.I(LI >_]?5A6Z?Q(/,[(SN? =>:-T4[PVZ1=6H_DF<3L-\%?BE=MNV(Z7) MNN7,EC DU^!2G9(;ZW:\:?O;4+YD\M+,3^0U:;MU1=O:"/I-.*JGFK:+C.YP ME_:L9YO2VG*V_/#EVPQ-^1BGX3N5UF/IOUGQA5O*CFT,Z 1_0";@MT39JU9V&7$!;J7]@M,(V"?^1 MVG# -EG6+I9L;-/:M**@1927+'_&6J6L/($ TG^.0% M'2(!#Y*,NCY D;@.US]!V7UAJ^T+\\]\BC3'4D.A0JC&U@!]=-+''BGS EAW MJ%&XC3@N;Y)8(ZM"^WOU\:"U ]$#Z27J,N1;%GK(,PA^JLPH:;C MEVJ0)(94>Y2-=?+URO5I(=GWA^I2X-%;]9' R5<3H?V)X5+-F)?T;T;*/R)) M_];D_P%02P,$% @ J#C,5K4&.@3^ P 4 L !8 !T;3(S,3@S-C)D M,5]E>#DY+3(N:'1M[591;]LV$'XWX/]P2X&B!4S+=H$!M35C2>VVP9S8B-T- M?:3%LT6$(C62DJO]^AVI*$G7/F18'C9@00 G]-UWWQV_^Z3TX^YJ->_WTH_+ M\P5]0OA)=Y>[U7*>)NTG?9OK!>?8;O[O%K^='8PVD]A/"H][&2!#J[Q M!#>FX'K0'@Q@BU8>SBB14C==GL^GA[=OA)$TNB/;F+P7_"?K.RBU7E8-WQI;&S<^W[]:3-_W>N=85(5PA>JF/ W!522,*?X.I+.1-:0C5 M24?@5&&[8./1& 0J6:,E'K7D0/.]YO5+;[G &50N)&^6BT5W4O &ZH"=">YU+&+" ]<"W"-\UB$-E4SA!5RJZ$P%J>0 M)J'3>?IIGGM?NFF2>"M=N&@E#^@R.T<#FO=C_Q$[>:>>[*TEW'K?H:?,Q^FAH M=6@0.:D!QK A:%=99$L=ED; #1ZC..$RK(]A:QT0C@V\VBQO+M=L-'[]P,#Y M2C210I0==+*+:W:W8 _:@U?=$I74J2'MQG"P@[A M%TZ#Q1RN:.K\#ZH&!VL*^/F*.P(D% AM MM:*B*L2?S-I!0X8\[/<>?)G*_6_._RIS[J!^8 S>2U1B"AM^)-5O\?]*,7IZ>U-,X<=PMC>6%'U_ M=J'((F!,7)Q14A"?S==XD>CCOM.$:G;E'Y%. NN6V?,.)@EOQ.TK&UL4$L! A0# M% @ J#C,5A7)\5>_# J)8 !4 ( !E T &UT86,M M,C R,S V,3)?;&%B+GAM;%!+ 0(4 Q0 ( *@XS%;B<5 2@@@ )5G 5 M " 88: !M=&%C+3(P,C,P-C$R7W!R92YX;6Q02P$"% ,4 M " "H.,Q6,SB*\*$G /OP $@ @ $[(P =&TR,S$X M,S8R9#%?.&LN:'1M4$L! A0#% @ J#C,5BK3T$AJ'@